Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo método basado en la utilización de luz para medicamentos empleados en el tratamiento contra el cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20131025006
Publicado:
02/01/2015
Caducidad:
21/02/2015
Resumen:
Investigadores de una universidad británica han desarrollado una metodología que utiliza luz de infrarrojo cercano (NIR) con potencial para reducir la toxicidad de algunos medicamentos empleados en el tratamiento contra el cáncer. La principal ventaja de la metodología es que permite utilizar medicamentos actuales contra el cáncer que implican un alto riesgo. La universidad busca socios con el fin de establecer acuerdos comerciales con opción a licencia exclusiva.

Details

Tittle:
Novel use of light to turn on cancer treatment drug
Summary:
Researchers at a North West UK University have developed a methodology using near infra-red light (NIR) that has the potential to reduce toxicity in some cancer treatment drugs. The main advantage being that this methodology permits the use of currently high risk cancer treatment drugs. The developer offers an opportunity for commercial involvement with an optional exclusive licence.
Description:
Members of the Combretastatin family possess varying ability to cause vascular disruption in tumors. Combretastatin binds to the β (beta)-subunit of tubulin at what is called the colchicine site, referring to the previously discovered vascular disrupting agent colchicine. Inhibition of tubulin polymerization prevents cancer cells from producing microtubules. Microtubules are essential to cytoskeleton production, intercellular movement, cell movement, and formation of the mitotic spindle used in chromosome segregation and cellular division. The anti-cancer activity from this action results from a change in shape in vasculature endothelial cells. Endothelial cells treated with Combretastatin rapidly balloon in shape causing a variety of effects which result in necrosis of the tumor core. Combretastatin based drugs affect vascular function and are currently in clinical trials, but in the past have shown issues with toxicity. Researchers at a North West University have discovered that In-situ conversion of Combretastatins from the inactive trans (on the other other side) isomer to the highly cytotoxic cis (on the same side) form (Cis and trans isomers occur both in organic molecules and in inorganic coordination complexes) using near infra-red light (NIR) has the promise of reducing this problem.
This development allows a relatively safer possibility for endoscopic application to treat a range of tumours.
e.g. thyroid, ovary, lung, bowel, pancreas in addition to skin cancers
This application also has potential for treatment of wet age-related macular degeneration (AMD). The project has reached the stage where commercial involvement is now required to fund further development work and to bring to market in exchange for an exclusive licence.
Advantages and Innovations:
The Innovations are:
Targeted activation by NIR light
NIR can penetrate tissue, enabling activation only at the site of the tumour, reducing risks to healthy tissue

With the advantages that:
The development allows the less toxic trans prodrug (a prodrug is a medication that is initially administered to the body in an inactive (or less than fully active) form, and then becomes converted to its active form through the normal metabolic processes of the body) to be administered, potentially reducing unwanted side effects to the patient.
In-situ activation for reduced toxicity
NIR can penetrate tissue, enabling activation only at the site of the tumour, reducing risks to healthy tissue
Stage of Development:
Available for demonstration
IPs:
Secret Know-how

Partner sought

Type and Role of Partner Sought:
It is unlikely that a small organisation will have the the necessary financial and other resources to contribute to this project and the ideal would be a company already engaged in the production of medical euqipment associated with cancer treatment. The partner's role would be to finance further final development and bring to market under an exclusive licence arrangement.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología